Vision community, FDA discuss use of PROs to improve labeling of ophthalmic treatments, products
The vision community is discussing with the Food and Drug Administration how vision-related patient-reported outcomes might be used in improving the labeling of ophthalmic treatments and products. The group — composed of researchers, clinicians, policymakers and representatives from industry and vision associations — attended a one-day symposium sponsored by the National Institutes of Health's National Eye Institute and the FDA on October 13, 2009.